JNJ
Johnson & Johnson
Company Overview
jnj.comJohnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...als, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Fundamental Snapshot
Company Info
Valuation
Profitability
Risk / Health
Interpretation:
8-9: Very Strong
5-7: Stable
0-4: Weak (Risk)
Interpretation:
> 3.0: Safe Zone
1.8 - 3.0: Grey Zone
< 1.8: Distress Zone (High Risk)
Interpretation:
< -1.78: Unlikely Manipulator
> -1.78: Possible Manipulator
Price (1Y)
Revenue Growth (YoY)
9.1%
Revenue CAGR (3Y)
1.2%
Revenue CAGR (5Y)
1.8%
Earnings CAGR (3Y)
13.3%
FCF CAGR (3Y)
11.2%
FCF CAGR (5Y)
1.8%
Industry Benchmark: Drugs (Pharmaceutical)
228 firms | Source: DamodaranPE (Current)
335.3x
PE (Forward)
24.2x
P/S
5.63x
EV/EBITDA
15.2x
ROE
24.0%
Net Margin
18.5%
Income & Cash Flow
Revenue ($B)
Gross Profit ($B)
Operating Income ($B)
Net Income ($B)
Free Cash Flow ($B)
Op. Cash Flow ($B)
Expenses
Cost of Revenue ($B)
Operating Expenses ($B)
R&D Expense ($B)
SG&A Expense ($B)
Cash & Debt
Cash & Equivalents ($B)
Total Debt ($B)
Net Debt ($B)
Shareholders' Equity ($B)
Shares, Dividends & Valuation
Shares Outstanding (B)
Dividends Paid ($B)
P/E Ratio
P/S Ratio
EV/EBITDA
Price vs FCF Fair Value
Avg: 16.3xPrice vs OCF Fair Value
Avg: 19.9xPrice vs Earnings Fair Value
Avg: 23.6xPrice vs EBIT Fair Value
Avg: 18.5xPrice vs EBITDA Fair Value
Avg: 14.1xPrice vs Sales Fair Value
Avg: 4.7xSegment KPIs
Coming soon - custom metrics from company filings